Azor (Amlodipine Besylate / Olmesartan Medoxomil) - Published Studies

Azor Related Published Studies

Well-designed clinical trials related to Azor (Amlodipine / Olmesartan)

A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil +/- hydrochlorothiazide. [2011.06]

Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies. [2009.01]

Well-designed clinical trials possibly related to Azor (Amlodipine / Olmesartan)

Immunogenicity and reactogenicity of a combined adsorbed tetanus toxoid, low dose diphtheria toxoid, five component acellular pertussis and inactivated polio vaccine in six-year-old children. [2005.03]

Other research related to Azor (Amlodipine / Olmesartan)

Changes in biomarkers and 24 hours blood pressure in hypertensive African Americans with the metabolic syndrome: comparison of amlodipine/olmesartan versus hydrochlorothiazide/losartan. [2013]

Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity. [2011.06]

Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. [2011.05.01]

A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide. [2011]

Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. [2010.08]

Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination. [2008.11]

Amlodipine/ARB fixed-dose combinations for the treatment of hypertension: focus on amlodipine/olmesartan combination. [2008.06]

Other possibly related research studies

Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954. [2010.03.01]

Overcoming therapeutic inertia in patients with hypertension. [2010.01]

Overcoming clinical inertia to achieve blood pressure goals: the role of fixed-dose combination therapy. [2010.04]